ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Ocio EM, Efebera YA, Hájek R, Straub J, Maisnar V, Eveillard JR, Karlin L, Mateos MV, Oriol A, Ribrag V, Richardson PG, Norin S, Obermüller J, Bakker NA, Pour L.
Ocio EM, et al. Among authors: obermuller j.
Haematologica. 2024 Mar 1;109(3):867-876. doi: 10.3324/haematol.2023.283490.
Haematologica. 2024.
PMID: 37646657
Free PMC article.
Clinical Trial.